REMINDER: Our user survey closes TODAY, please submit your responses here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Thanks folks much appreciated, and agree there is exciting stuff in the pipeline! I’m holding patiently on a bit of a loss from badly timed entry here, might have a deeper look again before averaging down. Any thoughts on cash burn rate wrt delays from covid-19? At present very quick-look, annual cash burn should last roughly another year... Am I missing any clinical milestone/collaboration payments? Possibility of Covid-19 grants or - dare I say it - revenue?
COVID-19
However, with great challenges come great opportunity and social obligation. The primary burden on healthcare systems caused by SARS-CoV-2 infection is the hyperinflammatory response which leads to the need for mechanical ventilation and admission to intensive care. There is a clear and urgent need for an immunomodulatory therapeutic to prevent or reduce hyperinflammation associated with severe disease.
As the scientific community's understanding of the immunology of COVID-19 has developed it became clear that the unique immunomodulatory activity of MRx-4DP0004 may be able to address this critical gap in the management of COVID-19 - to prevent or reduce hyperinflammation in hospitalised patients. 4D is conducting a Phase II placebo-controlled trial to demonstrate clinical benefit in addition to standard of care. The trial has received expedited acceptance from the UK's MHRA, and preparations are advancing quickly to begin dosing patients.
Nothing really outstanding about it in my opinion as its more of the business position in the past, but £22m was raised for a purpose, so next RNS should be more juicy
These where last years results as expected. We have the placing money this year so the balance sheet looks much better. Many exciting things ongoing within the company & many news flows to come soon.
Any thoughts on these annual results? Nice to see an impressive summary of progress on all the clinical lines, but struggling to see anything really new... Overall seems positive to my eyes, but I’m relatively new into 4D.